Related Experiment Video

Updated: Apr 28, 2026

Biochemical Titration of Glycogen In vitro
07:16

Biochemical Titration of Glycogen In vitro

Published on: November 24, 2013

27.9K

1,5-Anhydroglucitol and glycated albumin in glycemia

Masafumi Koga

    Advances in Clinical Chemistry
    |June 19, 2014
    PubMed

    Insights

    Monitoring diabetes involves various blood glucose tests like HbA1c, glycated albumin (GA), and 1,5-anhydroglucitol (1,5 AG). While HbA1c is standard, GA and 1,5 AG offer better short-term and post-meal glucose insights.

    Area of Science:

    • Endocrinology
    • Clinical Chemistry
    • Diabetes Management

    Background:

    • Diabetic chronic complications necessitate stringent glycemic control.
    • Current strategies focus on maintaining plasma glucose levels close to normal.
    • Understanding glycemic control indices is crucial for effective diabetes treatment.

    Purpose of the Study:

    • To review measurement, usage, evidence, and limitations of glycemic control indices.
    • To compare HbA1c with other markers like glycated albumin (GA) and 1,5-anhydroglucitol (1,5 AG).
    • To highlight the importance of selecting appropriate glycemic markers for diabetes management.

    Main Methods:

    • Literature review on glycemic control markers.
    • Analysis of measurement techniques and clinical applications.
    • Comparison of HbA1c, GA, fructosamine, and 1,5 AG.

    Main Results:

    • HbA1c reflects long-term control but has limitations in short-term changes and specific patient groups (e.g., anemia).
    • GA and 1,5 AG offer insights into intermediate- and short-term glycemic control.
    • Both GA and 1,5 AG are not affected by hemoglobin metabolism and reflect postprandial glucose levels.

    Conclusions:

    • HbA1c is the gold standard but has limitations.
    • GA and 1,5 AG provide valuable complementary information for glycemic monitoring.
    • Appropriate selection of glycemic control indices is essential for optimal diabetes care.

    More Related Videos

    Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

    Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

    Published on: March 7, 2025

    1.2K
    Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo10:35

    Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

    Published on: April 6, 2022

    2.7K

    Related Concept Videos

    Hyperglycemia01:29

    Hyperglycemia

    Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
    24
    Hormones Regulating Blood Glucose01:16

    Hormones Regulating Blood Glucose

    Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
    In addition to accelerating glucose uptake and utilization, insulin has...
    7.4K
    Hypoglycemia01:26

    Hypoglycemia

    Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
    27
    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
    1.3K
    Diabetic Nephropathy01:28

    Diabetic Nephropathy

    Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
    28
    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are...
    949